ライフサイエンスコーパス: duloxetine

1 age drug fragment couplings (e.g., flutamide-duloxetine).

2 uated these sex differences in the effect of duloxetine.

3 ioural response of Caenorhabditis elegans to duloxetine.

4 ct animals, rats of neither sex responded to duloxetine.

5 o may respond optimally to therapies such as duloxetine.

6 d randomized trial comparing placebo pill to duloxetine.

7 a moderate recommendation for treatment with duloxetine.

8 e followed by placebo or placebo followed by duloxetine.

9 nanomolar range and is comparable to that of duloxetine.

10 significantly increased starting at 120 mg/d duloxetine.

11 utility was 0.52 for nortriptyline, 0.43 for duloxetine, 0.05 for pregabalin, and 0.00 for mexiletine

12 erotonin-norepinephrine reuptake inhibitors (duloxetine, 0.71%; venlafaxine, 1.54%), a tricyclic anti

13 icantly at 2 weeks of treatment with 80 mg/d duloxetine (11.3 at baseline, 3.4 at 240 mg/d, P<0.001).

14 n treatments (CBT: 10.2, escitalopram: 11.1, duloxetine: 11.2).

15 SUCRA-based relative ranking of treatments, duloxetine 120 mg was associated with higher efficacy fo

16 Duloxetine 120 mg was associated with the highest improv

17 lowing doses were compared: 60-mg and 120-mg duloxetine; 150-mg, 300-mg, 450-mg, and 600-mg pregabali

18 with CBT (16 1-hour sessions) or medication (duloxetine 30-60 mg/day or escitalopram 10-20 mg/day).

19 gine (56%), followed by oxcarbazepine (46%), duloxetine (30%), carbamazepine (26%), topiramate (25%),

20 One was a 10-week trial of duloxetine (30-120 mg daily; mean 92.1 mg/day [SD 30.00]

21 treatment with escitalopram (10-20 mg/day), duloxetine (30-60 mg/day), or CBT (16 50-minute sessions

22 treatments (CBT: 41.9%, escitalopram: 46.7%, duloxetine: 54.7%).

23 , subjects were randomly assigned to receive duloxetine 60 mg twice a day (n = 104) or placebo (n = 1

24 lind, placebo-controlled, active-referenced (duloxetine 60 mg), parallel-group study evaluated the sh

25 Duloxetine, a serotonin and norepinephrine reuptake inhi

26 Duloxetine, a serotonin-norepinephrine reuptake inhibito

27 was rapidly normalized by spinal delivery of duloxetine acting via 5-hydroxytryptamine type 2A recept

28 rate a role of neuroendocrine stress axes in duloxetine analgesia (anti-hyperalgesia) for the treatme

29 enrolled patients, 127 patients treated with duloxetine and 128 who received placebo were evaluable f

30 s for the study were that the indication for duloxetine and a direct measurement of depression severi

31 Duloxetine and comparator SSRI.

32 orepinephrine/serotonin reuptake inhibitors (duloxetine and milnacipran) in fibromyalgia.

33 onin and norepinephrine-reuptake inhibitors--duloxetine and milnacipran--and the anticonvulsant prega

34 adrenaline re-uptake inhibitors, for example duloxetine and milnacipran.

35 difference in the average pain score between duloxetine and placebo was 0.73 (95% CI, 0.26-1.20).

36 Duloxetine and SSRI did not differ in efficacy, and comp

37 serotonin-norepinephrine reuptake inhibitor, duloxetine and the serotonin selective reuptake inhibito

38 settings, the analgesic actions of the SNRI duloxetine and the SSRI fluoxetine were differentially a

39 IRs were similar among duloxetine and untreated patients (0.5/1000 PY [95 % CI:

40 mm Hg (PD30) increased dose-dependently with duloxetine and was significant at the end of the 120-mg/

41 er day for amitriptyline, 120 mg per day for duloxetine, and 600 mg per day for pregabalin).

42 s in the synthesis of ezetimibe, dapoxetine, duloxetine, and atomoxetine.

43 with amitriptyline (off-label), pregabalin, duloxetine, and milnacipran (on-label) in reducing fibro

44 e treatment of fibromyalgia, but pregabalin, duloxetine, and milnacipran are the only pharmacological

45 drugs as first-line therapy, or tramadol or duloxetine as second-line therapy.

46 Individuals receiving duloxetine as their initial 5-week treatment reported a

47 veral other pharmaceutical agents, including duloxetine, atomoxetine, fluoxetine and tolterodine.

48 We find that duloxetine binds to several metabolic enzymes and change

49 Furthermore, duloxetine blunted an increase in corticosterone induced

50 done, phenelzine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine, and agomel

51 clinical trial, we found that treatment with duloxetine, but not placebo, normalized DMN connectivity

52 cumulation of the widely used antidepressant duloxetine by using click chemistry, thermal proteome pr

53 modafinil, levodopa, rotigotine, clozapine, duloxetine, clonazepam, ramelteon, gabapentin, zonisamid

54 arge, randomized placebo-controlled trial of duloxetine collected before and 8 weeks after treatment.

55 py-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in

56 Duloxetine compared with placebo improved (pooled risk d

57 0.82 points lower for patients who received duloxetine compared with those who received placebo (95%

58 these cultures with the L1 mimetic compounds duloxetine, crotamiton, and trimebutine rescued impaired

59 There was strong evidence of duloxetine, desvenlafaxine, and levomilnacipran increasi

60 Paroxetine, duloxetine, desvenlafaxine, and venlafaxine were associa

61 udy evaluates the association of exposure to duloxetine during pregnancy and the risk of major and mi

62 r stillbirth was associated with exposure to duloxetine during pregnancy.

63 uncovered in 6/19 participants a tendency of duloxetine enhancing predicted placebo response, while i

64 line, bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, fluvoxamine, levom

65 depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milna

66 line, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtaz

67 Duloxetine exerts only modest relief of male stress urin

68 ted of more than 2 million births with 1,512 duloxetine-exposed pregnancies.

69 Duloxetine-exposed versus duloxetine-nonexposed PS-match

70 Duloxetine-exposed women were compared with 4 comparator

71 , amitriptyline, citalopram, desvenlafaxine, duloxetine, fluoxetine, fluvoxamine, mirtazapine, nefazo

72 ignificantly fewer discontinuations than did duloxetine, fluvoxamine, paroxetine, reboxetine, and ven

73 , patients were randomized to receive either duloxetine followed by placebo or placebo followed by du

74 Conclusion Results of treatment with duloxetine for AIMSS were superior to those of placebo a

75 mantadine for BD, retinoic acid for MDD, and duloxetine for CTP.

76 e behavioral therapy (CBT), escitalopram, or duloxetine for major depressive disorder.

77 ing to the antidepressant venlafaxine XR (or duloxetine for those not eligible to receive venlafaxine

78 with increases in total cholesterol and, for duloxetine, glucose concentrations, despite all drugs re

79 stress urinary incontinence, confirming that duloxetine had a modest positive effect in men with post

80 Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse even

81 njections provide short-term pain relief and duloxetine has demonstrated efficacy.

82 pion hydrochloride, citalopram hydrobromide, duloxetine hydrochloride, escitalopram oxalate, fluoxeti

83 Effects of duloxetine hydrochloride, selective serotonin reuptake i

84 Duloxetine improved but did not resolve urinary incontin

85 study further examines the hepatic safety of duloxetine in a large US health insurance database.

86 thalamic-pituitary-adrenal, to the effect of duloxetine in preclinical models of oxaliplatin- and pac

87 antidepressant medications (escitalopram and duloxetine) in patients with major depression and examin

88 gher but not statistically significant among duloxetine initiators compared to initiators of venlafax

89 hepatic-related death or liver failure among duloxetine initiators compared to venlafaxine and possib

90 Among 30,844 duloxetine initiators, 21,000 were matched to venlafaxin

91 Duloxetine is a selective serotonin-norepinephrine reupt

92 is ineffective for acute low back pain, and duloxetine is associated with modest effects for chronic

93 Fetal safety of duloxetine is not well established.

94 Duloxetine is the only agent that has appropriate eviden

95 Duloxetine is the only treatment for CIPN currently reco

96 tes CIPN, and that the therapeutic effect of duloxetine is thought to be mediated, at least in part,

97 Duloxetine is US Food and Drug Administration approved f

98 , or vilazodone) or an SNRI (desvenlafaxine, duloxetine, levomilnacipran, milnacipran, or venlafaxine

99 munity of accumulators and non-accumulators, duloxetine markedly altered the composition of the commu

100 Duloxetine (MD -3.13, 95% credible interval [CrI] -4.13

101 ndomized to receive nortriptyline (n = 134), duloxetine (n = 126), pregabalin (n = 73), or mexiletine

102 ived treatment with escitalopram (n = 22) or duloxetine (n = 14) for 10 weeks.

103 cebo and active-comparator phase 3 trials of duloxetine (n = 2515).

104 cally antagonized NET by a range of doses of duloxetine [(+)-N-methyl-3-(1-naphthalenyloxy)-2 thiophe

105 naline reuptake inhibitors, mainly including duloxetine (nine of 14 studies); 7.7 (6.5-9.4) for prega

106 Duloxetine-exposed versus duloxetine-nonexposed PS-matched analyses showed odds ra

107 women were compared with 4 comparators: (1) duloxetine-nonexposed women; (2) selective serotonin reu

108 olerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0.31, 95% CrI 0.13 to 0.95)

109 ine were significantly more efficacious than duloxetine (odds ratios [OR] 1.39, 1.33, 1.30 and 1.27,

110 neuroendocrine stress axes in the effect of duloxetine on CIPN, rats of both sexes were submitted to

111 n that stress may impact response of CIPN to duloxetine, open new approaches to the treatment of CIPN

112 first week and 2 capsules of either 30 mg of duloxetine or placebo daily for 4 additional weeks.

113 Patients were randomly assigned 1:1 to duloxetine or placebo for 13 weeks.

114 of taking 1 capsule daily of either 30 mg of duloxetine or placebo for the first week and 2 capsules

115 as by randomizing patients to receive either duloxetine or placebo, and it supported true causal infe

116 ed 65 or above were treated by vortioxetine, duloxetine or placebo.

117 e randomly assigned to receive escitalopram, duloxetine, or CBT monotherapy and completed 12 weeks of

118 of treatment withcognitive behavior therapy, duloxetine, or escitalopram were prospectively monitored

119 For example, high-dose duloxetine outperformed escitalopram in treating core em

120 early superior medication, nortriptyline and duloxetine outperformed pregabalin and mexiletine when p

121 ised after 2 weeks of treatment with 80 mg/d duloxetine (P<0.001), the lowest dose used in the study.

122 talytic protocol for the synthesis of an (S)-duloxetine precursor.

123 Most guidelines recommend amitriptyline, duloxetine, pregabalin, or gabapentin as initial analges

124 xine-exposed women; and (4) women exposed to duloxetine prior to, but not during, pregnancy.

125 ns were collected in 32 participants for the duloxetine RCT and 34 participants for the desvenlafaxin

126 ween Jan 26, 2006, and Nov 22, 2011, for the duloxetine RCT and Aug 5, 2012, and Jan 28, 2016, for th

127 away linearly modeled placebo analgesia from duloxetine response, we uncovered in 6/19 participants a

128 Gabapentin and duloxetine reversed mechanical hyperalgesia but did not

129 e and alprazolam (RR = 1.86); loratadine and duloxetine (RR = 1.94); loratadine and ropinirole (RR =

130 ound that our selected compounds tacrine and duloxetine significantly improved remyelination in the p

131 lafaxine (SMD, -1.53 [CrI, -2.41 to -0.65]), duloxetine (SMD, -1.33 [CrI, -1.82 to -0.86]), and amitr

132 Duloxetine, strontium ranelate, and NGF antibodies are p

133 nctional connectivity compared with placebo (duloxetine study: beta=-0.06; 95% CI -0.08 to -0.03; p<0

134 depressive symptom severity in both studies (duloxetine study: r=0.38, 95% CI 0.01-0.65; p=0.0426; de

135 n supplemented with amitriptyline (P-A), and duloxetine supplemented with pregabalin (D-P), each path

136 gabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatmen

137 sion and without liver disease who initiated duloxetine to comparators (venlafaxine or selective sero

138 in another 6/19, we uncovered a tendency for duloxetine to diminish it.

139 nd in the wastewater effluent ranged from 3 (duloxetine) to 2190 ng/L (venlafaxine), whereas individu

140 line, escitalopram, citalopram, mirtazapine, duloxetine, trazodone, fluoxetine, bupropion, paroxetine

141 th placebo-treated female subjects (n = 92), duloxetine-treated female subjects (n = 92) demonstrated

142 verse events of any grade were higher in the duloxetine-treated group (78% v 50%); rates of grade 3 a

143 improvement on most efficacy measures, while duloxetine-treated male subjects (n = 12) failed to impr

144 Plasma from duloxetine-treated subjects (ex vivo effect) dose-depend

145 Compared with placebo-treated subjects, duloxetine-treated subjects had significantly greater re

146 Compared with placebo-treated subjects, duloxetine-treated subjects improved significantly more

147 Duloxetine treatment improved fibromyalgia symptoms and

148 Hepatic injury has been reported following duloxetine use.

149 ty-nine percent of those initially receiving duloxetine vs 38% of those initially receiving placebo r

150 efficacious; and 51 of 134 [38.1%] quit), of duloxetine was 0.80 (95% CrI, 0.68-0.92; 29 of 126 [23.0

151 Duloxetine was administered in a randomized, placebo-con

152 trial (with a 1-week placebo lead-in phase), duloxetine was an effective and safe treatment for many

153 Duloxetine was approved for the treatment of chronic kne

154 onic low back pain than previously observed, duloxetine was effective for chronic low back pain, and

155 Duloxetine was not significantly different from placebo

156 Duloxetine was safely administered and well tolerated.

157 xel-induced painful peripheral neuropathy to duloxetine, we demonstrate a major contribution to its e

158 Systemic administration of duloxetine, which alone had no effect on nociceptive thr

159 newly developed ones, such as pregabalin and duloxetine, while specifically marketed for diabetic neu

160 The primary hypothesis was that duloxetine would be more effective than placebo in decre

161 We hypothesized that treatment of AIMSS with duloxetine would improve average joint pain compared wit